Cmxtwenty is a Milwaukee based pharmaceutical company focused on development of a unique lipid compound to be used as a non-narcotic treatment for pain. CMX-020 is an analog of arachidonic acid, a common endogenous lipid and one of the most abundant fatty acids in the brain. The mechanisms of action and chemical structure of CMX-020 are similar to AM404, the active metabolite of acetaminophen. However, CMX-020 is not toxic to the liver. CMX-020 also treats pain with the efficacy of todays narcotic drugs, but is believed to be less addictive and does not depress the respiratory system. In animal studies, CMX-020 has no analgesic ceiling, similar to morphine. With intravenous administration of CMX-020, the PK characteristics are similar to fentanyl: it is immediately effective after administration, and has a plasma and efficacy half-life of approximately 35 minutes. With dose titration providing a wide-range of efficacy and a short half-life, intravenous CMX-020 is uniquely suited for controlling varying levels of pain in a hospital setting. An oral version of CMX-020, which utilizes enteric coated softgels and a proprietary delivery vehicle, provides efficacy through 6-8 hours in human studies. In animal studies, CMX-020 is effective in osteoarthritis, diabetic neuropathy, chemotherapy induced neuropathy, fibromyalgia, and sciatica indications. Cmxtwenty has completed a Phase 1 studies with both oral and intravenous products and has initiated Phase 2 POC studies with oral CMX-020 in patients with sciatica in Adelaide Australia.